ROIV

Roivant Sciences Ltd. (ROIV) - Q3 2026 (Period Ended Dec 31, 2025) Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2025, and the nine months ended on that date. Roivant Sciences Ltd. is a biopharmaceutical company operating through a "Vant" structure of subsidiaries to develop and commercialize medicines. The company currently has no approved commercial products following the sale of Dermavant in October 2024 and is focused on advancing its pipeline, including brepocitinib (Priovant), IMVT-1402 and batoclimab (Immunovant), and mosliciguat (Pulmovant).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported a net loss from continuing operations of $313.7 million for the quarter and $753.7 million for the nine-month period.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased to $2.0 million for the quarter (from $9.0 million in Q3 2024) and $5.7 million for the nine months (from $21.5 million in the prior year), primarily due to lower license agreement revenue at Genevant.
• Increased Operating Expenses: Total operating expenses rose to $341.2 million for the quarter (from $283.4 million) and $936.0 million for the nine months (from $850.2 million).
  • R&D: Increased by $23.8 million (quarter) and $77.7 million (nine months), driven by program progression (mosliciguat, brepocitinib, anti-FcRn franchise) and higher share-based compensation.
  • G&A: Increased by $33.5 million (quarter) and $7.9 million (nine months). The quarterly increase included a $17.1 million impairment charge related to the relocation of the U.S. corporate headquarters and higher share-based compensation.
• Discontinued Operations: The prior year periods included significant income from discontinued operations ($327.0 million for Q3 2024 and $373.0 million for the nine months) related to the sale of Dermavant. No such income was recorded in the current period.
• Investment Fair Value: The company recognized an unrealized loss of $21.6 million on investments (Arbutus and Datavant) for the quarter, compared to a gain of $21.3 million in the prior year quarter.

Guidance, Outlook, and Risks

• Liquidity: Management states that existing cash, cash equivalents, and marketable securities ($4.5 billion) are sufficient to fund operations for the foreseeable future. No immediate need for additional capital is anticipated.
• Pipeline Catalysts:
  • Priovant: Positive Phase 2 results for brepocitinib in cutaneous sarcoidosis announced in February 2026. NDA filed for dermatomyositis. Phase 3 topline data for non-infectious uveitis expected in H2 2026.
  • Immunovant: Potentially registrational trial for IMVT-1402 in difficult-to-treat rheumatoid arthritis fully enrolled; topline data expected H2 2026. Batoclimab Phase 3 topline data in thyroid eye disease expected H1 2026.
  • Pulmovant: Phase 2 trial of mosliciguat fully enrolled; topline data expected H2 2026.
• Capital Actions: Immunovant completed an underwritten offering in December 2025 raising approximately $543.6 million in net proceeds. Roivant authorized a new $500 million share repurchase program in June 2025; no purchases made under this new authorization as of Dec 31, 2025.
• Risks:
  • Regulatory Uncertainty: Risks associated with FDA staffing reductions and potential delays in review processes.
  • Intellectual Property: Ongoing litigation regarding LNP patents (Genevant/Arbutus vs. Moderna) with a jury trial scheduled for March 2026. A European patent was recently revoked by the EPO Board of Appeal.
  • License Agreements: Immunovant relies on the HanAll Agreement for core IP; termination would adversely affect development.

Investor Verification Checklist

• Cash Runway: Verify the burn rate against the $4.5 billion liquidity position to confirm the "foreseeable future" funding claim.
• Impairment Charge: Review the details of the $17.1 million impairment related to the U.S. headquarters relocation to assess if further facility costs are pending.
• Share-Based Compensation: Analyze the impact of the Priovant Exchange Offer and Senior Executive Compensation Program on future non-cash expenses.
• Investment Volatility: Monitor the fair value of Arbutus and Datavant holdings, which significantly impact reported net income/loss.
• Legal Proceedings: Track the outcome of the Genevant/Arbutus vs. Moderna patent litigation scheduled for March 2026.
• Immunovant Financing: Confirm the utilization of the $543.6 million raised by Immunovant and its impact on Roivant's consolidated cash position.